KRT18 and metabolic dysfunction-associated steatohepatitis: Further research, including larger-scale clinical studies or combination of serum sCD14 and other non-invasive biomarkers of NASH such as CK18, are needed to fully investigate the diagnostic and therapeutic implications of our findings.